Post-essential Thrombocythemia Myelofibrosis (PET-MF)
3 clinical trials · Condition
◉ Watch Post-essential Thrombocythemia Myelofibrosis (PET-MF)
| Record | Firm | Date |
|---|---|---|
| A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) (NCT07357727) | Novartis Pharmaceuticals | 2026-06-16 |
| MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) (NCT07362225) | MPN Research Foundation | 2025-09-26 |
| Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) (NCT03136185) | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 2017-07-18 |
Track Post-essential Thrombocythemia Myelofibrosis (PET-MF) automatically
Every clearance here is in the API, with alerts when new ones post.